PD-L1 was upregulated in ovarian cancers, and anti-PD-L1 therapy could increase the proportion of CD4+ and CD8+ T cell (about 20%) and reduce regulatory T cell (about 5%) in mouse ovarian cancer model to promote tumor rejection (38, 39). This evidence concerns the gene CD274 and neoplasm.